These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 2291562)

  • 1. Design, properties, and effective use of the oral chelator L1 and other alpha-ketohydroxypyridines in the treatment of transfusional iron overload in thalassemia.
    Kontoghiorghes GJ
    Ann N Y Acad Sci; 1990; 612():339-50. PubMed ID: 2291562
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients.
    Olivieri NF; Templeton DM; Koren G; Chung D; Hermann C; Freedman MH; McClelland RA
    Ann N Y Acad Sci; 1990; 612():369-77. PubMed ID: 2291564
    [No Abstract]   [Full Text] [Related]  

  • 3. Deferiprone for the treatment of transfusional iron overload in thalassemia.
    Belmont A; Kwiatkowski JL
    Expert Rev Hematol; 2017 Jun; 10(6):493-503. PubMed ID: 28448199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial.
    Kersten MJ; Lange R; Smeets ME; Vreugdenhil G; Roozendaal KJ; Lameijer W; Goudsmit R
    Ann Hematol; 1996 Nov; 73(5):247-52. PubMed ID: 8959943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Roberts DJ; Rees D; Howard J; Hyde C; Alderson P; Brunskill S
    Cochrane Database Syst Rev; 2005 Oct; (4):CD004450. PubMed ID: 16235363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deferiprone approved for iron overload.
    Traynor K
    Am J Health Syst Pharm; 2011 Nov; 68(22):2106. PubMed ID: 22058092
    [No Abstract]   [Full Text] [Related]  

  • 7. Oral iron chelation: a review with special emphasis on Indian work on deferiprone (L1).
    Agarwal MB
    Indian J Pediatr; 1993; 60(4):509-16. PubMed ID: 8262587
    [No Abstract]   [Full Text] [Related]  

  • 8. Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases.
    Kontoghiorghes GJ
    Indian J Pediatr; 1993; 60(4):485-507. PubMed ID: 8262586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
    Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A review.
    Kontoghiorghes GJ
    Analyst; 1995 Mar; 120(3):845-51. PubMed ID: 7741239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
    Kontoghiorghes GJ; Aldouri MA; Hoffbrand AV; Barr J; Wonke B; Kourouclaris T; Sheppard L
    Br Med J (Clin Res Ed); 1987 Dec; 295(6612):1509-12. PubMed ID: 3122880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospects for effective oral iron chelation therapy in man with 1,2-dimethyl-3-hydroxypyrid-4-one and other alpha-ketohydroxypyridines.
    Kontoghiorghes GJ; Bartlett AN; Hoffbrand AV
    Prog Clin Biol Res; 1989; 309():107-14. PubMed ID: 2780745
    [No Abstract]   [Full Text] [Related]  

  • 13. Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions.
    Kontoghiorghes GJ
    Hemoglobin; 2006; 30(2):183-200. PubMed ID: 16798643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies of the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one in thalassemia patients.
    Olivieri NF; Koren G; St Louis P; Freedman MH; McClelland RA; Templeton DM
    Semin Hematol; 1990 Apr; 27(2):101-4. PubMed ID: 2190316
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term therapy with deferiprone.
    Olivieri NF
    Acta Haematol; 1996; 95(1):37-48. PubMed ID: 8604585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
    Barman Balfour JA; Foster RH
    Drugs; 1999 Sep; 58(3):553-78. PubMed ID: 10493280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral deferiprone for iron chelation in people with thalassaemia.
    Roberts DJ; Brunskill SJ; Doree C; Williams S; Howard J; Hyde CJ
    Cochrane Database Syst Rev; 2007 Jul; (3):CD004839. PubMed ID: 17636775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
    Kontoghiorghes GJ; Kolnagou A
    Haematologica; 2006 Jun; 91(6 Suppl):ELT04. PubMed ID: 16785141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of deferiprone and deferrioxamine for the treatment of transfusional iron overload in children with beta thalassemia major.
    Waheed N; Ali S; Butt MA
    J Ayub Med Coll Abbottabad; 2014; 26(3):297-300. PubMed ID: 25671931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemical, pharmacological, toxicological and therapeutic advances of deferiprone (L1) and other iron and aluminium chelators.
    Kontoghiorghes GJ
    Arch Toxicol Suppl; 1996; 18():202-14. PubMed ID: 8678796
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.